WO2010057117A3 - Topical transdermal drug delivery compositions - Google Patents

Topical transdermal drug delivery compositions Download PDF

Info

Publication number
WO2010057117A3
WO2010057117A3 PCT/US2009/064629 US2009064629W WO2010057117A3 WO 2010057117 A3 WO2010057117 A3 WO 2010057117A3 US 2009064629 W US2009064629 W US 2009064629W WO 2010057117 A3 WO2010057117 A3 WO 2010057117A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
drug delivery
agent
transdermal drug
Prior art date
Application number
PCT/US2009/064629
Other languages
French (fr)
Other versions
WO2010057117A2 (en
Inventor
John G. Guerra
Original Assignee
Helm Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helm Pharmaceuticals, Inc. filed Critical Helm Pharmaceuticals, Inc.
Publication of WO2010057117A2 publication Critical patent/WO2010057117A2/en
Publication of WO2010057117A3 publication Critical patent/WO2010057117A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to topical drug compositions and methods for topical drug delivery which promote stability of a drug component and facilitate the penetration of the drug component into the skin of the host. Provided are topical drug compositions containing a suitable pharmaceutical agent agent, such as a vasoactive agent, and/or anti-inflammatory agents, NSAIDs, and/or non-NSAIDs. Also provided are methods for effectively utilizing the compositions for delivering said active agent to the host. These compositions and methods are useful for the transdermal drug delivery and treatment of a number of diseases and disorders in mammals. The invention also relates to methods for formulating or preparing the compositions of the present invention. To minimize irritation, the composition is water based, and preferably does not contain alcohol and/or alkyl hydroxybenzoate preservatives.
PCT/US2009/064629 2008-11-14 2009-11-16 Topical transdermal drug delivery compositions WO2010057117A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11481608P 2008-11-14 2008-11-14
US11483608P 2008-11-14 2008-11-14
US11461608P 2008-11-14 2008-11-14
US61/114,616 2008-11-14
US61/114,816 2008-11-14
US61/114,836 2008-11-14

Publications (2)

Publication Number Publication Date
WO2010057117A2 WO2010057117A2 (en) 2010-05-20
WO2010057117A3 true WO2010057117A3 (en) 2010-09-16

Family

ID=42170779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/064629 WO2010057117A2 (en) 2008-11-14 2009-11-16 Topical transdermal drug delivery compositions

Country Status (1)

Country Link
WO (1) WO2010057117A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017069793A1 (en) * 2015-10-22 2017-04-27 Enertopia Corporation Vaginal gel compositions and methods of use thereof
WO2018081427A1 (en) 2016-10-26 2018-05-03 Revive Pharmaceuticals, Llc Treating sexual dysfunction
CA3049670A1 (en) * 2017-01-08 2018-07-12 Olive Therapeutics, LLC Treatment of sexual dysfunction

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5948416A (en) * 1995-06-29 1999-09-07 The Procter & Gamble Company Stable topical compositions
US20040265383A1 (en) * 2003-06-27 2004-12-30 Han Cui Compositions for parenteral administration and sustained-release of therapeutic agents
US20060127483A1 (en) * 2004-12-10 2006-06-15 Alan Drizen Topical drug delivery system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5948416A (en) * 1995-06-29 1999-09-07 The Procter & Gamble Company Stable topical compositions
US20040265383A1 (en) * 2003-06-27 2004-12-30 Han Cui Compositions for parenteral administration and sustained-release of therapeutic agents
US20060127483A1 (en) * 2004-12-10 2006-06-15 Alan Drizen Topical drug delivery system

Also Published As

Publication number Publication date
WO2010057117A2 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
WO2012160180A3 (en) Pharmaceutical composition for administration to nails
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
NZ703808A (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
WO2009053741A3 (en) Novel formulation
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
WO2011079234A3 (en) Highly permeating terbinafine formulation for treating onychomycosis
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
EA200901112A1 (en) LIQUID COMPOSITIONS FORMING DERMAL FILMS FOR INTRODUCTION OF MEDICINAL PREPARATIONS IN THE SKIN
WO2010070675A3 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
MX2010008802A (en) Liquid formulation of fsh.
CL2009002183A1 (en) Use of a topical composition comprising 2.5% of imiquimod and a pharmaceutically acceptable vehicle to prepare a medicament useful for treating actinic keratosis; topical composition.
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
WO2011041478A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
WO2009022338A3 (en) Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
MX2011012143A (en) Compositions suitable for the topical treatment of fungal infections of the skin and nails.
MY161607A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
WO2008107092A3 (en) Use of derivatives of 4-hydroxyphenoxy acetic acid
WO2012161497A3 (en) Peptide derivatives having a superior moisturizing effect and uses thereof
UA96794C2 (en) Glucocorticoides, method of use thereof, treatment method and pharmaceutical formulation based thereon
EP1798234A4 (en) Pharmaceutical composition comprising temozolomide ester
CL2009001267A1 (en) Compounds derived from nitrogenous tricycles, with antibacterial activity; preparation procedure; pharmaceutical composition comprising them; for the treatment of tuberculosis.
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09826928

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 24.08.2011.)

122 Ep: pct application non-entry in european phase

Ref document number: 09826928

Country of ref document: EP

Kind code of ref document: A2